* 1. **Title.** [Racial/Ethnic Disparities in Hepatocellular Carcinoma Treatment and Survival in California, 1988-2012]

**1.2 Running title.** [Hepatocellular Carcinoma Treatment and Survival Disparities]

**1.3-1.4 Authorship and Institutions.** [Susan L. Stewart, [[1]](#footnote-1) Sandy L. Kwong[[2]](#footnote-2), Christopher L. Bowlus,[[3]](#footnote-3) Tung T. Nguyen,[[4]](#footnote-4) Annette E. Maxwell,[[5]](#footnote-5) Roshan Bastani, [[6]](#footnote-6) Eric W. Chak[[7]](#footnote-7), Moon S. Chen, Jr.[[8]](#footnote-8) Note all authors are fluent in English.]

**1.5 Author contributions.** [SLS, SLK, MSC contributed substantially to the conception and design of the study, acquisition of data, analyses and interpretation of data, drafting the article, making critical revisions, and final approval of the submitted article. CLB, TTN, AEM, RB, and EWC provided important intellectual contributions to the content of the manuscript and approved the final version of the manuscript.]

**1.6 Supportive foundations.** [The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries, under cooperative agreement 5NU58DP003862-04/DP003862; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute.  The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California, Department of Public Health, the National Cancer Institute, and the CDC or their Contractors and Subcontractors is not intended nor should be inferred. Additionally, the preparation of this paper was supported in part by grants from the National Cancer Institute U54CA153499 and the Centers for Disease Control and Prevention, 1U51PS004633. However, the views expressed are those of the authors and do not necessarily express the views of the U.S. Department of Health and Human Services.]

**1.7 Institutional review board statement.** [Not applicable for cancer registry studies that are conducted for the purpose of surveillance.]

**1.8 Informed consent statement.** [Not applicable.]

**1.9 Conflict-of-interest statement.** [CLB and MSC have served as consultants to Gilead Science, Inc. All of the other authors have no conflicts.

**1.10 Data sharing statement**. [Not applicable.]

**1.11 Correspondence to.** [Moon S. Chen, Jr., Ph.D., M.P.H., Professor and Associate Director, Cancer Control, UC Davis Comprehensive Cancer Center, 2450 48th Street, Suite 1600, Sacramento, CA 95817, USA.]

**1.12** **Telephone and fax.** [Tel. 1-916-734-1191. Fax. 1-916-703-5003.]

**1.13 Abstract.** [See manuscript.]

**1.14 Keywords.** [disparities; treatment; survival; liver cancer; hepatocellular carcinoma]

**1.15 Core tip.** [Our paper analyzes 33270 cases of hepatocellular carcinoma by treatment and survival data dis-aggregated into 15 racial/ethnic categories over a 25-year period from the world’s largest cancer registry in a single geo-political jurisdiction. Such granularity provides more precise identification of populations at risk by race/ethnicity, age, gender, stage of diagnosis, type of surgery, and other variables not previously examined.]

**1.16 Citation. [**Stewart SL, Kwong SL, Bowlus CL, Nguyen TT, Maxwell AE, Bastani R, Chak EW, Chen MS Jr. Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012.]

**1.17 Main text.** [See manuscript.]

**1.18 Biostatistics.** [The first two authors are biostatisticians: Susan L. Stewart, Ph.D. and Sandy L. Kwong, M.P.H. They affirm that the statistical analyses reported in this paper.]

**1.19 Units**. [Only standard units were used.]

**1.20 Illustrations.** [See manuscript.]

**1.21 Tables**. [Done in accordance with guidelines.]

**1.22 Notes in illustrations and tables.** [Done in accordance with our understanding of the guidelines.]

**1.23 Abbreviations.** [Done in accordance with our understanding of the guidelines.]

**1.24 Italics.** [Done in accordance with our understanding of the guidelines.]

**1.25 Acknowledgements.** [Not applicable.]

**1.26 References.** [Done in accordance with our understanding of the guidelines.]

1. Division of Biostatistics, Department of Public Health Sciences, University of California, Davis School of Medicine—Sacramento, CA [↑](#footnote-ref-1)
2. California Department of Public Health—Sacramento, CA [↑](#footnote-ref-2)
3. Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of California, Davis School of Medicine—Sacramento, CA [↑](#footnote-ref-3)
4. Division of General Internal Medicine, University of California, San Francisco--San Francisco, CA [↑](#footnote-ref-4)
5. UCLA Kaiser Permanente Center for Health Equity, Fielding School of Public Health and Jonsson Comprehensive Cancer Center, University of California, Los Angeles—Los Angeles, CA [↑](#footnote-ref-5)
6. UCLA Kaiser Permanente Center for Health Equity, Fielding School of Public Health and Jonsson Comprehensive Cancer Center, University of California, Los Angeles—Los Angeles, CA, USA. [↑](#footnote-ref-6)
7. Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of California, Davis—Sacramento, CA, USA. [↑](#footnote-ref-7)
8. Division of Hematology and Oncology, Department of Internal Medicine, UC Davis School of Medicine and UC Davis Comprehensive Cancer Center—Sacramento, CA, USA. [↑](#footnote-ref-8)